In a landmark multicenter study led by researchers at the Icahn School of Medicine at Mount Sinai, an innovative electronic health record (EHR)-based marker has emerged as a promising tool for predicting and preventing organ rejection in adolescent transplant patients. This novel marker, known as the Medication Level Variability Index (MLVI), leverages fluctuations in routine immunosuppressant drug levels recorded in patient health records to flag inconsistencies in medication adherence—one of the critical factors leading to transplant failure. The implications of these findings, published in the American Journal of Transplantation, extend beyond liver transplantation to potentially transform chronic disease management and patient monitoring on a global scale.
The study encompassed 13 pediatric transplant centers across the United States and Canada, reviewing over 3,000 liver transplant recipients’ electronic health data. From this vast dataset, 148 adolescents and young adults were identified as high-risk for organ rejection based on their MLVI scores. Participants were then randomized to receive either standard post-transplant care or a two-year, telehealth-based behavioral intervention aimed at improving medication adherence. This remote intervention involved regular check-ins and support from trained specialists, providing a scalable and patient-centered approach to healthcare delivery.
While the primary endpoint—a composite measure assessing rejection incidents, need for retransplantation, and withdrawal of consent—did not reach statistical significance, this outcome was largely due to unexpectedly low rejection rates in both treatment groups. Notably, the group receiving behavioral intervention exhibited roughly half the number of rejection-related events compared to those under standard care. These findings underscore the potential clinical benefit of combining MLVI-guided risk stratification with proactive remote intervention to reduce organ rejection, minimizing severe complications before they arise.
Traditionally, transplant clinicians have struggled to objectively identify patients who inconsistently take their immunosuppressant medications, due to the reliance on self-reported adherence or expensive and laborious monitoring methods. MLVI innovates on these fronts by using intra-patient variability in drug blood concentrations—collected routinely during follow-up laboratory assessments—as an objective, quantifiable metric. Because transplant recipients undergo frequent therapeutic drug monitoring, MLVI harnesses existing clinical data streams, facilitating risk assessment without additional burden or cost.
Eyal Shemesh, MD, Chief of Behavioral and Developmental Health at Mount Sinai Kravis Children’s Hospital and lead investigator of the study, highlighted the profound shift this technology enables: “Our findings show that we can detect early nonadherence by using data already embedded in electronic health records, allowing clinicians to intervene proactively, a strategy years ahead of reactive treatment post-rejection.” Dr. Shemesh’s dual expertise in pediatrics and psychiatry informs a nuanced understanding of adolescent health behaviors in the transplant context, emphasizing the study’s translational potential.
Adolescents and young adults represent a particularly vulnerable demographic in transplant care due to developmental, psychological, and social challenges that affect consistent medication use. The MLVI marker and subsequent remote intervention address these challenges by tailoring care management to individual risk profiles. This precision medicine approach not only improves outcomes but could also alleviate healthcare system burdens by reducing hospitalizations and retransplant rates, thereby preserving scarce donor organs and enhancing quality of life for recipients.
An integral component of the study’s success was its innovative telehealth platform, which maintained continuous engagement with patients through the COVID-19 pandemic, a period that intensified healthcare access disparities. Through virtual check-ins, behavioral coaching, and personalized support, the intervention demonstrated that even high-risk patients could achieve sustained adherence. This model suggests new avenues for scalable, resource-efficient care delivery, adaptable to broad clinical settings beyond transplantation.
Benjamin L. Shneider, MD, senior author and Chief of Gastroenterology at Texas Children’s Hospital, emphasized the practical implications: “This study paves the way for early detection and intervention for nonadherence before life-threatening rejection occurs. The use of MLVI combined with remote behavioral support offers a blueprint to optimize pediatric liver transplant outcomes and may revolutionize chronic disease management for children and families worldwide.”
George Mazariegos, MD, Chair of the Starzl Network for Excellence in Pediatric Transplantation, reinforced the broader impact, noting that early behavioral correction informed by objective risk markers could reshape lifelong care strategies for transplant recipients. His position at a leading pediatric transplant center amplifies the significance of incorporating MLVI into clinical workflows to systematically improve patient trajectories.
Despite the encouraging clinical trends, researchers acknowledge that the intervention’s efficacy, efficiency, and cost-effectiveness require further rigorous evaluation. Nonetheless, the study provides compelling evidence supporting the integration of MLVI into routine post-transplant care protocols, moving clinical practice toward preemptive, data-driven management rather than reliance on reactive measures after complications arise.
This novel application of electronic health record data analytics marks a critical advance in personalized transplant medicine. By capturing medication adherence patterns objectively and remotely intervening to support behavioral change, healthcare teams can stabilize graft function, reduce morbidity, and extend graft survival. The convergence of routine lab data, telehealth innovation, and behavioral science exemplifies the future of precision medicine in complex chronic conditions.
Funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health, this research underscores the power of collaborative, multicenter efforts to tackle persistent challenges in transplant medicine. As healthcare systems increasingly digitize, leveraging EHR-derived metrics like MLVI for proactive patient management may extend well beyond transplantation to improve outcomes across numerous chronic illnesses.
In conclusion, this study establishes MLVI as a transformative, objective risk stratification tool and confirms the feasibility and promise of remote behavioral interventions in improving medication adherence among adolescent transplant patients. This paradigm shift from reaction to prevention has the potential to revolutionize transplant care and pave the way for broader applications in chronic disease management, illustrating the profound impact of integrating electronic health records with innovative clinical strategies.
Subject of Research:
Medication nonadherence and risk stratification in adolescent liver transplant recipients using an EHR-derived marker to predict and prevent organ rejection.
Article Title:
A remote intervention to improve medication nonadherence guided by a marker of risk derived from the electronic health records of adolescent transplant recipients.
News Publication Date:
June 15, 2026
Web References:
https://www.mountsinai.org
https://www.texaschildrens.org
https://doi.org/10.1016/j.ajt.2026.04.03
References:
American Journal of Transplantation, Article DOI: 10.1016/j.ajt.2026.04.03, Published May 27, 2026
Keywords:
Transplantation, Medication adherence, Electronic health records, Adolescents, Liver transplantation, Immunosuppressant variability, Remote behavioral intervention, Telehealth, Chronic disease management, Organ rejection prevention, Pediatric transplant care, Precision medicine
